You are here: Home » 0 » » Archives for 0st

Information on the total number of voting rights and shares

REGULATED INFORMATION

Information on the total number of voting rights and shares

Mont–Saint–Guibert (Belgium), July 7, 2021, 10:30 pm CET / 4:30 pm ET "" In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of 2,835,000 new shares on July 7, 2021 pursuant to a capital increase in connection with Nyxoah's initial public offering in the United States.

  • Share capital: EUR 4,295,126.64
  • Total number of securities carrying voting rights: 25,002,609 (all ordinary shares)
  • Total number of voting rights (= denominator): 25,002,609 (all relating to ordinary shares)
  • Number of rights to subscribe to securities carrying voting rights not yet issued:
  • 91 "2013 ESOP Warrants" issued on 3 May 2013 and 23 December 2014, entitling their holders to subscribe to a total number of 45,500 securities carrying voting rights (all ordinary shares);
  • 365 "2016 ESOP Warrants" issued on 3 November 2016, entitling their holders to subscribe to a total number of 182,500 securities carrying voting rights (all ordinary shares);
  • 319 "2018 ESOP Warrants" issued on 12 December 2018, entitling their holders to subscribe to a total number of 159,500 securities carrying voting rights (all ordinary shares); and
  • 550,000 "2020 ESOP Warrants" issued on 21 February 2020, entitling their holders to subscribe to a total number of 550,000 securities carrying voting rights (all ordinary shares).

*

* *

For further information, please contact:

Nyxoah
Fabian Suarez, CFO
corporate@nyxoah.com
+32 (0)10 22 24 55

Gilmartin Group
Vivian Cervantes
IR@nyxoah.com

Attachment


GLOBENEWSWIRE (Distribution ID 1000515085)

NeoTX Hosting Key Opinion Leader Webinar on Overcoming Check Point Inhibitor Resistance

REHOVOT, Israel, July 07, 2021 (GLOBE NEWSWIRE) — NeoTX Therapeutics (NeoTX), a clinical–stage immuno–oncology company, announced today that it will host a key opinion leader (KOL) webinar on overcoming checkpoint inhibitor resistance on Wednesday, July 14, 2021 at 10am Eastern Time.

The webinar will feature a presentation by KOL Mario Sznol, MD, Yale Cancer Center, who will discuss New Frontiers for Checkpoint Inhibitors in Immuno–Oncology. NeoTX's management will also give an update on their Tumor Targeted Superantigen (TTS) platform's lead candidate, naptumomab estafenatox (NAP) in overcoming resistance. NAP is being evaluated in combination with chemotherapy, checkpoint inhibitors and CAR T. Dr. Sznol and NeoTX management will be available to answer questions following the formal presentations.

To register for the webinar, please click here.

Dr. Mario Sznol is Professor of Internal Medicine, Leader of the Melanoma–Renal Cancer Disease–Associated Translational Research Team, and Co–Leader of the Cancer Immunology Program at the Yale Cancer Center, New Haven, CT. Dr. Sznol graduated from Rice University and Baylor College of Medicine (BCM) in Houston, Texas. He trained in internal medicine at BCM and completed a medical oncology fellowship in the Department of Neoplastic Diseases, Mount Sinai Hospital, New York. He spent the next twelve years in the Biologics Evaluation Section (BES), Investigational Drug Branch (IDB), Cancer Therapy Evaluation Program of the National Cancer Institute, and was Head of the BES from 1994–1999. He attended on the inpatient units of the Biological Response Modifiers Program, NCI, from 1988–1996 and the Immunotherapy Service of the Surgery Branch, NCI, from 1997–1999. From 1999–2004, he served as Vice President of Clinical Development and Executive Officer of Vion Pharmaceuticals in New Haven, Connecticut, and joined the faculty at Yale in 2004. Dr. Sznol is a past President of the Society for Immunotherapy of Cancer. Dr. Sznol's areas of interest include early drug development, immunotherapy clinical trials, and treatments for advanced melanoma and renal cancer.

About NeoTX
NeoTX is a clinical–stage immuno–oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an effective response. The company's lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information, please visit www.neotx.com.

Media Contact:
Elizabeth Miller, MD
LifeSci Communications
(704) 299–6016
emiller@lifescicomms.com


GLOBENEWSWIRE (Distribution ID 8276845)